Voiant expands clinical trial imaging services into obesity, metabolic disease research

• DFW Capital Partners portfolio company Voiant launched clinical trial imaging services for obesity and metabolic disease studies.
• Expansion targets demand for imaging endpoints beyond weight or BMI, including body composition and metabolic outcomes.
• Voiant will use MRI and DXA capabilities with centralized quality control to deliver regulatory-ready imaging endpoints for sponsors.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DFW Capital Partners LP published the original content used to generate this news brief on August 05, 2026, and is solely responsible for the information contained therein.